Oncocyte (NASDAQ:IMDX – Get Free Report) announced its earnings results on Monday. The company reported ($0.19) earnings per share for the quarter, Zacks reports. The company had revenue of $0.56 million for the quarter.
Here are the key takeaways from Oncocyte’s conference call:
- The FDA said the clinical data in the initial GraftAssureDx submission did not yet support the proposed intended use and requested additional evidence, including an independent accuracy study and expert biopsy-slide reviews. The company expects to submit its response before the January 21, 2027 deadline, but authorization and U.S. launch timing remain dependent on FDA review.
- Insight has begun enrolling patients in its GALACTIC registry, with about five sites expected to be enrolling by year-end, and says beta-site comparisons have shown performance equivalent to legacy tests. Management expects the registry and beta program to generate some revenue and increase clinical familiarity, while cautioning that near-term revenue will be modest.
- The company said transplant centers representing slightly more than 5% of U.S. kidney transplants are committed to developing in-house testing and could launch in 2027. Initial commercialization would focus on larger centers in MolDX jurisdictions, though broader uptake depends on local validation and reimbursement.
- Operating expenses declined from their Q4 2025 peak, with R&D expense at $3.8 million in Q3 versus $5.8 million at the peak; management said operating expenses excluding non-cash items were flat year over year. It also said free cash flow improved and that the FDA-related spending burden is winding down.
- Insight added urine testing for T-cell-mediated rejection to its pipeline and is pursuing heart-transplant testing, with a possible heart submission in the second half of 2027. It also expects to submit kidney and heart applications in Europe around year-end or early January, but said limited reimbursement there currently constrains commercialization.
Oncocyte Trading Down 10.2%
IMDX opened at $1.92 on Tuesday. The stock has a 50-day moving average price of $3.25 and a 200-day moving average price of $4.53. Oncocyte has a 12-month low of $1.85 and a 12-month high of $7.56.
Wall Street Analyst Weigh In
A number of equities analysts have commented on IMDX shares. Wall Street Zen cut shares of Oncocyte from a “hold” rating to a “sell” rating in a research note on Saturday, October 3rd. Weiss Ratings restated a “sell (d-)” rating on shares of Oncocyte in a research report on Monday, September 21st. Finally, Needham & Company LLC restated a “buy” rating and set a $9.00 price objective on shares of Oncocyte in a research report on Tuesday, August 18th. Two investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $10.50.
View Our Latest Stock Analysis on Oncocyte
Oncocyte Company Profile
Oncocyte Corporation, now known as Insight Molecular Diagnostics, Inc. (NASDAQ: IMDX), is a molecular diagnostics company focused on monitoring organ transplants. Its tests analyze donor-derived cell-free DNA in a transplant recipient’s blood to help assess graft health and identify signs of potential injury or rejection. The company’s VitaGraft tests include assays for kidney and liver transplant monitoring. These laboratory-developed tests are processed through the company’s clinical laboratory and are intended to provide clinicians with information that can complement other aspects of post-transplant care.
Read More
- Five stocks we like better than Oncocyte
- Tyson Foods’ 10% Surge Puts a Breakout in Sight, But Wall Street Remains Cautious
- Microsoft’s Outage Barely Moved Its Stock, But a Bigger Risk May Be Building
- MongoDB’s Biggest Advantage May Be GitLab’s Biggest Weakness
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
Receive News & Ratings for Oncocyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oncocyte and related companies with MarketBeat.com's FREE daily email newsletter.
